Platelet Function and Response to Aspirin: Gender-Specific Features and Implications for Female Thrombotic Risk and Management

ABSTRACT

This article reviews gender-specific differences in platelet function and response to aspirin. In contrast with men, women under 65 years of age do not benefit from aspirin therapy in primary prevention of coronary artery disease. Furthermore, the overall mortality after myocardial infarction is higher among women, which cannot simply be explained by age or individual treatment. Platelets play a central role in thrombo-ischemic events leading to myocardial infarction and ischemic stroke. Gender differences in platelet reactivity and “aspirin resistance” have been reported. Several studies using female platelets have shown increased platelet reactivity at baseline and a less effective inhibition of platelet aggregation by aspirin. The mechanisms underlying these differences are still to be elucidated, but influences of female sex hormones may play an important role. As a consequence, inhibition of platelet aggregation in women treated with aspirin may be insufficient, and female patients might benefit from higher maintenance dosages or the use of alternative antiplatelet medications. A potential future role of pharmacogenomics and laboratory monitoring of antiplatelet medications in predicting individual responsiveness is likely. Overall, primary prevention of myocardial infarction in women should be correlated with the individual risk score of the female patient. More studies focused on women are needed to optimize gender-specific therapy and, therefore, to improve clinical outcomes in women with atherosclerosis.

KEYWORDS

Sex-differences - women - coronary artery disease - platelets - aspirin

REFERENCES

• 1 Ridker P M, Cook N R, Lee I M et al.. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.  N Engl J Med. 2005;  352 1293-1304
• 2 Hansson L, Zanchetti A, Carruthers S G HOT Study Group et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.  Lancet. 1998;  351 1755-1762
• 3 de Gaetano G. Collaborative Group of the Primary Prevention Project . Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice.  Lancet. 2001;  357 89-95
• 4 Kjeldsen S E, Kolloch R E, Leonetti G et al.. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.  J Hypertens. 2000;  18 629-642
• 5 Steering Committee of the Physicians' Health Study Research Group . Final report on the aspirin component of the ongoing Physicians Health Study.  N Engl J Med. 1989;  321 129-135
• 6 Peto R, Gray R, Collins R et al.. Randomised trial of prophylactic daily aspirin in British male doctors.  Br Med J (Clin Res Ed). 1988;  296 313-316
• 7 The Medical Research Council's General Practice Research Framework . Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk.  Lancet. 1998;  351 233-241
• 8 Gattellari M, Worthington J, Zwar N. Warfarin: an inconvenient truth.  Stroke. 2009;  40 5-7
• 9 Vaccarino V, Parsons L, Every N R, Barron H V, Krumholz H M. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants.  N Engl J Med. 1999;  341 217-225
• 10 Hochman J S, Tamis J E, Thompson T D et al.. Sex, clinical presentation and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators.  N Engl J Med. 1999;  341 226-232
• 11 Johnson M, Ramey E, Ramwell P W. Sex and age differences in human platelet aggregation.  Nature. 1975;  253 355-357
• 12 Stevens R F, Alexander M K. A sex difference in the platelet count.  Br J Haematol. 1977;  37 295-300
• 13 Zwierzina W D, Kunz F, Kogelnig R, Herold M. Sex-related differences in platelet aggregation in native whole blood.  Thromb Res. 1987;  48 161-171
• 14 Kelton J G, Carter C J, Santos A, Hirsh J. Sex related differences in platelet function: the effect of aspirin.  Blood. 1982;  59 625-627
• 15 Harrison M J, Weisblatt E. A sex difference in the effect of aspirin on “spontaneous” platelet aggregation in whole blood.  Thromb Haemost. 1983;  50 773-774
• 16 Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray P F. Platelet hyperreactivity in women from families with premature atherosclerosis.  J Am Med Womens Assoc. 2003;  58 272-277
• 17 Leng X H, Hong S Y, Larrucea S et al.. Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males.  Arterioscler Thromb Vasc Biol. 2004;  24 376-381
• 18 Meade T W, Vickers M V, Thompson S G, Stirling Y, Haines A P, Miller G J. Epidemiological characteristics of platelet aggregability.  Br Med J (Clin Res Ed). 1985;  290 428-432
• 19 Faraday N, Goldschmidt-Clermont P J, Bray P F. Gender differences in platelet GPIIb-IIIa activation.  Thromb Haemost. 1997;  77 748-754
• 20 Becker D M, Segal J, Vaidya D et al.. Sex differences in platelet reactivity and response to low-dose aspirin therapy.  JAMA. 2006;  295 1420-1427
• 21 Ivandic B T, Giannitsis E, Schlick P, Staritz P, Katus H A, Hohlfeld T. Determination of aspirin responsiveness by use of whole blood platelet aggregometry.  Clin Chem. 2007;  53 614-619
• 22 Favaloro E J. Clinical utility of the PFA-100.  Semin Thromb Hemost. 2008;  34 709-733
• 23 Favaloro E J. Clinical application of the PFA-100.  Curr Opin Hematol. 2002;  9 407-415
• 24 Favaloro E J. The utility of the PFA-100 in the identification of von Willebrand disease: a concise review.  Semin Thromb Hemost. 2006;  32 537-545
• 25 Favaloro E J. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100^® and von Willebrand factor collagen-binding activity as coupled strategies.  Semin Thromb Hemost. 2006;  32 566-576
• 26 Kundu S K, Heilmann E J, Sio R, Garcia C, Davidson R M, Ostgaard R A. Description of an in vitro platelet function analyzer—PFA-100.  Semin Thromb Hemost. 1995;  21(Suppl 2) 106-112
• 27 Cho Y U, Jang S, Park C J, Chi H S. Variables that affect platelet function analyzer-100 (PFA-100) closure times and establishment of reference intervals in Korean adults.  Ann Clin Lab Sci. 2008;  38 247-253
• 28 Böck M, De Haan J, Beck K H et al.. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives.  Br J Haematol. 1999;  106 898-904
• 29 Sestito A, Sciahbasi A, Landolfi R, Maseri A, Lanza G A, Andreotti F. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age.  Cardiologia. 1999;  44 661-665
• 30 Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert U T, Hellstern P. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals.  Br J Haematol. 2005;  130 759-767
• 31 Porto I, Leone A M, Nanni L et al.. Interplay of platelet polymorphisms, risk factors, and von Willebrand factor in determining collagen-adenosine diphosphate PFA-100 results in patients with coronary artery disease.  Blood Coagul Fibrinolysis. 2005;  16 97-104
• 32 Cho Y U, Chi H S, Jang S, Park C J. [Reconfirmation of preanalytical variables and establishment of reference intervals of platelet function analyzer-100 closure times in Korean adults].  Korean J Lab Med. 2007;  27 318-323
• 33 Brockmann M A, Beythien C, Magens M M, Wilckens V, Kuehnl P, Gutensohn K. Platelet hemostasis capacity in smokers. In vitro function analyses with 3.2% citrated whole blood.  Thromb Res. 2001;  104 333-342
• 34 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables.  Thromb Haemost. 1997;  78 315-326
• 35 Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review.  Thromb Haemost. 2008;  99 14-26
• 36 Gum P A, Kottke-Marchant K, Poggio E D et al.. Profile and prevalence of aspirin resistance in patients with cardiovascular disease.  Am J Cardiol. 2001;  88 230-235
• 37 Abaci A, Caliskan M, Bayram F et al.. A new definition of aspirin non-responsiveness by platelet function analyzer-100 and its predictors.  Platelets. 2006;  17 7-13
• 38 Pamukcu B, Oflaz H, Onur I et al.. Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease.  Blood Coagul Fibrinolysis. 2007;  18 461-465
• 39 Hayward C P, Harrison P, Cattaneo M, Ortel T L, Rao A K. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis . Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.  J Thromb Haemost. 2006;  4 312-319
• 40 Smith Jr S C, Allen J, Blair S N AHA/ACC et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.  Circulation. 2006;  113 2363-2372
• 41 Weisman S M, Graham D Y. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.  Arch Intern Med. 2002;  162 2197-2202
• 42 Chen Z M, Sandercock P, Pan H C et al.. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups.  Stroke. 2000;  31 1240-1249
• 43 Maree A O, Fitzgerald D J. Aspirin and coronary artery disease.  Thromb Haemost. 2004;  92 1175-1181
• 44 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.  Semin Thromb Hemost. 1997;  23 349-356
• 45 Schafer A I. Antiplatelet therapy.  Am J Med. 1996;  101 199-209
• 46 Mousa S A, Forsythe M S, Bozarth J M, Reilly T M. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1.  Cardiology. 1993;  83 367-373
• 47 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
• 48 Antiplatelet Trialists' Collaboration . Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  BMJ. 1994;  308 81-106
• 49 ISIS-2 (Second international Study of Infarct Survival) collaborative group . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.  Lancet. 1988;  2 349-360
• 50 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
• 51 Becker R C, Meade T W, Berger P B American College of Chest Physicians et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133(6, Suppl) 776S-814S
• 52 Wenger N K. Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines—2007 Update.  Drugs. 2008;  68 339-358
• 53 Sanmuganathan P S, Ghahramani P, Jackson P R, Wallis E J, Ramsay L E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.  Heart. 2001;  85 265-271
• 54 Mosca L, Appel L J, Benjamin E J American Heart Association et al. Evidence-based guidelines for cardiovascular disease prevention in women.  Circulation. 2004;  109 672-693
• 55 Shafazand M, Schaufelberger M, Lappas G, Swedberg K, Rosengren A. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry.  Eur Heart J. 2008;  , December 24 (Epub a head of print)
• 56 Barrett-Connor E L, Cohn B A, Wingard D L, Edelstein S L. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study.  JAMA. 1991;  265 627-631
• 57 O'Sullivan J B, Mahan C M. Mortality related to diabetes and blood glucose levels in a community study.  Am J Epidemiol. 1982;  116 678-684
• 58 Legrand D A, Scheen A J. [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance].  Rev Med Liege. 2006;  61 682-690
• 59 Elsaesser A, Hamm C W. Acute coronary syndrome: the risk of being female.  Circulation. 2004;  109 565-567
• 60 Duvall W L, Vorchheimer D A. Multi-bed vascular disease and atherothrombosis: scope of the problem.  J Thromb Thrombolysis. 2004;  17 51-61
• 61 American Heart Association . Heart disease and stroke statistics – 2007 update.  Available at: http://circ.ahajournals.org Accessed June 29, 2007; 
• 62 Länne T, Ahlgren A R. Increased arterial stiffness in IDDM women—methodological considerations.  Diabetologia. 1996;  39 871-872
• 63 Hu J, Norman M, Wallensteen M, Gennser G. Increased large arterial stiffness and impaired acetylcholine induced skin vasodilatation in women with previous gestational diabetes mellitus.  Br J Obstet Gynaecol. 1998;  105 1279-1287
• 64 Pepine C J, Kerensky R A, Lambert C R et al.. Some thoughts on the vasculopathy of women with ischemic heart disease.  J Am Coll Cardiol. 2006;  47(3, Suppl) S30-S35
• 65 Vaccarino V, Parsons L, Every N R, Barron H V, Krumholz H M. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants.  N Engl J Med. 1999;  341 217-225
• 66 Lerner D J, Kannel W B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population.  Am Heart J. 1986;  111 383-390
• 67 Marrugat J, Sala J, Masiá R et al.. Mortality differences between men and women following first myocardial infarction. RESCATE Investigators. Recursos Empleados en el Síndrome Coronario Agudo y Tiempo de Espera.  JAMA. 1998;  280 1405-1409
• 68 Sanderson S, Emery J, Baglin T, Kinmonth A L. Narrative review: aspirin resistance and its clinical implications.  Ann Intern Med. 2005;  142 370-380
• 69 Berger J S, Roncaglioni M C, Avanzini F, Pangrazzi I, Tognoni G, Brown D L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.  JAMA. 2006;  295 306-313
• 70 Manson J E, Stampfer M J, Colditz G A et al.. A prospective study of aspirin use and primary prevention of cardiovascular disease in women.  JAMA. 1991;  266 521-527
• 71 Yerman T, Gan W Q, Sin D D. The influence of gender on the effects of aspirin in preventing myocardial infarction.  BMC Med. 2007;  5 29
• 72 Chen W H, Lee P Y, Ng W, Tse H F, Lau C P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.  J Am Coll Cardiol. 2004;  43 1122-1126
• 73 Mosca L, Banka C L, Benjamin E J on behalf of the Expert Panel/Writing Group et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update.  J Am Coll Cardiol. 2007;  49 1230-1250
• 74 Buchanan M R, Rischke J A, Butt R, Turpie A G, Hirsh J, Rosenfeld J. The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects.  Thromb Res. 1983;  29 125-139
• 75 Ho P C, Triggs E J, Bourne D W, Heazlewood V J. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites.  Br J Clin Pharmacol. 1985;  19 675-684
• 76 Miners J O, Grgurinovich N, Whitehead A G, Robson R A, Birkett D J. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid.  Br J Clin Pharmacol. 1986;  22 135-142
• 77 Ridker P M, Hennekens C H, Tofler G H, Lipinska I, Buring J E. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.  J Cardiovasc Risk. 1996;  3 209-212
• 78 Escolar G, Bastida E, Garrido M, Rodríguez-Gómez J, Castillo R, Ordinas A. Sex-related differences in the effects of aspirin on the interaction of platelets with subendothelium.  Thromb Res. 1986;  44 837-847
• 79 Gordon T, Kannel W B, Hjortland M C, McNamara P M. Menopause and coronary heart disease. The Framingham Study.  Ann Intern Med. 1978;  89 157-161
• 80 Rosenberg L, Hennekens C H, Rosner B, Belanger C, Rothman K J, Speizer F E. Early menopause and the risk of myocardial infarction.  Am J Obstet Gynecol. 1981;  139 47-51
• 81 Leinwand L A. Sex is a potent modifier of the cardiovascular system.  J Clin Invest. 2003;  112 302-307
• 82 Milcent C, Dormont B, Durand-Zaleski I, Steg P G. Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 nationwide French hospitals database.  Circulation. 2007;  115 833-839
• 83 Manson J E, Hsia J, Johnson K C Women's Health Initiative Investigators et al. Estrogen plus progestin and the risk of coronary heart disease.  N Engl J Med. 2003;  349 523-534
• 84 Frederiksen H, Ravenholt R T. Thromboembolism, oral contraceptives, and cigarettes.  Public Health Rep. 1970;  85 197-205
• 85 Rossouw J E, Anderson G L, Prentice R L Writing Group for the Women's Health Initiative Investigators et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288 321-333
• 86 Grady D, Wenger N K, Herrington D et al.. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.  Ann Intern Med. 2000;  132 689-696
• 87 Langer R D, Pradhan A D, Lewis C E et al.. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study.  Thromb Haemost. 2005;  93 1108-1116
• 88 Howard B V, Hsia J, Ouyang P et al.. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance.  Circulation. 2004;  110 201-206
• 89 Alexandersen P, Tankó L B, Bagger Y Z, Qin G, Christiansen C. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.  Climacteric. 2006;  9 108-118
• 90 Pelzer T, Shamim A, Wölfges S, Schumann M, Neyses L. Modulation of cardiac hypertrophy by estrogens.  Adv Exp Med Biol. 1997;  432 83-89
• 91 Grohe C, Briesmeister G, Stimpel L, Karas R H, Vetter H, Neyses L. Functional estrogen receptors in myocardial and myogenic cells.  Circulation. 1994;  90 I-538
• 92 Grohé C, Kahlert S, Löbbert K et al.. Modulation of hypertensive heart disease by estrogen.  Steroids. 1996;  61 201-204
• 93 Klein-Hitpass L, Schorpp M, Wagner U, Ryffel G U. An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells.  Cell. 1986;  46 1053-1061
• 94 Grohé C, Kahlert S, Löbbert K et al.. Cardiac myocytes and fibroblasts contain functional estrogen receptors.  FEBS Lett. 1997;  416 107-112
• 95 Spranger M, Aspey B S, Harrison M J. Sex difference in antithrombotic effect of aspirin.  Stroke. 1989;  20 34-37
• 96 Campbell C L, Smyth S, Montalescot G, Steinhubl S R. Aspirin dose for the prevention of cardiovascular disease: a systematic review.  JAMA. 2007;  297 2018-2024
• 97 Rumilla K, Chen D, Baudhuin L M. Pharmacogenetics in hemostasis: friend or foe?.  Semin Thromb Hemost. 2009;  35 42-49